DD1013 / Huadong Medicine - LARVOL DELTA

A novel GLP-1/GIP/Amylin triple agonist demonstrates robust weight loss and overcomes incretin plateau in preclinical models (EASD 2026) - "DD1013, a novel GLP-1/GIP/Amylin triple agonist, demonstrates robust and dose-dependent metabolic efficacy and effectively overcomes weight loss plateaus associated with dual-incretin therapies. Its favorable pharmacokinetic profile supports once-weekly dosing, and exploration of a long-acting formulation for potential monthly dosing is ongoing, highlighting its strong potential as a next-generation therapy for obesity."

Preclinical • Metabolic Disorders • Obesity